PSMAI cut-off value for mortality in men: 680.1 mm2/m2

Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients

Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177- PSMA-617 radioligand therapy, BMC Urology

The forest plots, Galbraith plot, sensitivity analysis, and subgroup

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study - ScienceDirect

SARCLISA® (isatuximab-irfc) ICARIA-MM Phase 3 Trial Results

ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer

ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer

Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study

EAU 2022: Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity

Immediate Mortality and Five-Year Survival of Employed Men with a First Myocardial Infarction

Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis

Yusuf BAĞ, Medical Doctor, Inonu University, Malatya, Department of General Surgery

Computed tomographic images at the the middle third lumbar vertebral